[
    {
     "kind": "calendar#event",
     "etag": "\"3271716041580000\"",
     "id": "fgmeqqke033kn2b5nscqhc85j8",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ZmdtZXFxa2UwMzNrbjJiNW5zY3FoYzg1ajggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2021-11-02T13:00:20.000Z",
     "updated": "2021-11-02T13:00:20.790Z",
     "summary": "INCY INCYTE PDUFA",
     "description": "2022-08-30 The NDA for use of parsaclisib in adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies will have a Standard Review and a PDUFA target action date of August 30, 2022. http://www.businesswire.com/news/home/20211101005269/en/Incyte-Announces-Acceptance-of-NDA-for-Parsaclisib-for-Three-Types-of-Relapsed-or-Refractory-Non-Hodgkin-Lymphomas",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-08-30"
     },
     "end": {
      "date": "2022-08-30"
     },
     "iCalUID": "fgmeqqke033kn2b5nscqhc85j8@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3275352013438000\"",
     "id": "o9a96l98o4dmn6psn30utvv8ns",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bzlhOTZsOThvNGRtbjZwc24zMHV0dnY4bnMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2021-11-23T14:00:06.000Z",
     "updated": "2021-11-23T14:00:06.719Z",
     "summary": "OBSV ObsEva SA PDUFA",
     "description": "2022-09-13 Linzagolix has a differentiated profile and if approved, would be the first and only GnRH receptor antagonist with flexible dosing options for uterine fibroids, including a low dose option to address the needs of women who cannot or do not want to take hormones.1,4 The FDA set a target action date of September 13, 2022 for this NDA under the Prescription Drug User Fee Act (PDUFA). https://www.sec.gov/Archives/edgar/data/0001685316/000119312521335829/d208050dex991.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-13"
     },
     "end": {
      "date": "2022-09-13"
     },
     "iCalUID": "o9a96l98o4dmn6psn30utvv8ns@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3276561613886000\"",
     "id": "ja9hgi1706o4r3h6hpipm1dvc8",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=amE5aGdpMTcwNm80cjNoNmhwaXBtMWR2YzggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2021-11-30T14:00:06.000Z",
     "updated": "2021-11-30T14:00:06.943Z",
     "summary": "BMY BRISTOL MYERS SQUIBB PDUFA",
     "description": "2022-09-10 U.S. Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process http://www.businesswire.com/news/home/20211129005192/en/Bristol-Myers-Squibb%E2%80%99s-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-U.S.-Food-and-Drug-Administration-and-Validated-by-European-Medicines-Agency",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-10"
     },
     "end": {
      "date": "2022-09-10"
     },
     "iCalUID": "ja9hgi1706o4r3h6hpipm1dvc8@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3285201628442000\"",
     "id": "16s7ivu4lun4ugnotga3qb1ico",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=MTZzN2l2dTRsdW40dWdub3RnYTNxYjFpY28gNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-01-19T14:00:14.000Z",
     "updated": "2022-01-19T14:00:14.221Z",
     "summary": "BLUE BLUEBIRD BIO, INC. PDUFA",
     "description": "2022-09-16 The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of September 16, 2022. http://www.businesswire.com/news/home/20220118005544/en/bluebird-Provides-Update-on-FDA-Review-Timelines-for-Betibeglogene-Autotemcel-beti-cel-for-Beta-Thalassemia-and-Elivaldogene-Autotemcel-eli-cel-for-Cerebral-Adrenoleukodystrophy-CALD",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-16"
     },
     "end": {
      "date": "2022-09-16"
     },
     "iCalUID": "16s7ivu4lun4ugnotga3qb1ico@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3292286424602000\"",
     "id": "5a21c4iejauc5dmgqo64ospp30",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=NWEyMWM0aWVqYXVjNWRtZ3FvNjRvc3BwMzAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-03-01T14:00:12.000Z",
     "updated": "2022-03-01T14:00:12.301Z",
     "summary": "HRTX HERON THERAPEUTICS, INC. /DE/ PDUFA",
     "description": "2022-09-17 The NDA for HTX-019 for PONV was submitted in November 2021 and the FDA set a PDUFA goal date of September 17, 2022. https://www.sec.gov/Archives/edgar/data/0000818033/000156459022007608/hrtx-ex991_6.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-17"
     },
     "end": {
      "date": "2022-09-17"
     },
     "iCalUID": "5a21c4iejauc5dmgqo64ospp30@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3299536809494000\"",
     "id": "c8e6bf9645s7df0kkddrqbgkr0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=YzhlNmJmOTY0NXM3ZGYwa2tkZHJxYmdrcjAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-04-12T13:00:04.000Z",
     "updated": "2022-04-12T13:00:04.747Z",
     "summary": "SPPI SPECTRUM PHARMACEUTICALS, INC. PDUFA",
     "description": "2022-09-09 The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of September 9, 2022. http://www.businesswire.com/news/home/20220411005203/en/Spectrum-Pharmaceuticals-Announces-FDA-Acceptance-of-BLA-Resubmission-for-Eflapegrastim",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-09"
     },
     "end": {
      "date": "2022-09-09"
     },
     "iCalUID": "c8e6bf9645s7df0kkddrqbgkr0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3301264812288000\"",
     "id": "ljoscf9acsppslage2pkdt6kq8",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bGpvc2NmOWFjc3Bwc2xhZ2UycGtkdDZrcTggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-04-22T13:00:06.000Z",
     "updated": "2022-04-22T13:00:06.144Z",
     "summary": "RVNC REVANCE THERAPEUTICS, INC. PDUFA",
     "description": "2022-09-08 Revance was provided a Prescription Drug User Fee Act (PDUFA) goal date of September 8, 2022. http://www.businesswire.com/news/home/20220421006042/en/Revance-Receives-FDA-Acceptance-of-BLA-Resubmission-for-DaxibotulinumtoxinA-for-Injection-for-Glabellar-Lines",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-08"
     },
     "end": {
      "date": "2022-09-08"
     },
     "iCalUID": "ljoscf9acsppslage2pkdt6kq8@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3301264826334000\"",
     "id": "qo72b9ktri1ha8ukn76bv2ut0c",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=cW83MmI5a3RyaTFoYTh1a243NmJ2MnV0MGMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-04-22T13:00:13.000Z",
     "updated": "2022-04-22T13:00:13.167Z",
     "summary": "REGN REGENERON PHARMACEUTICALS, INC. PDUFA",
     "description": "2022-09-19 FDA decision on sBLA (target action date of September 19, 2022) and EC decision on regulatory submission for NSCLC, chemotherapy combination (second half 2022) https://www.sec.gov/Archives/edgar/data/0000872589/000093041322000790/c103581_defa14a.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-19"
     },
     "end": {
      "date": "2022-09-19"
     },
     "iCalUID": "qo72b9ktri1ha8ukn76bv2ut0c@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3302301612200000\"",
     "id": "qedtvhim9ibul32g3tsfr9830k",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=cWVkdHZoaW05aWJ1bDMyZzN0c2ZyOTgzMGsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-04-28T13:00:06.000Z",
     "updated": "2022-04-28T13:00:06.100Z",
     "summary": "FENC Fennec Pharmaceuticals Inc. PDUFA",
     "description": "2022-09-23 The PDUFA target action date for the NDA is September 23, 2022. https://www.globenewswire.com/news-release/2022/04/27/2429948/0/en/Fennec-Pharmaceuticals-Announces-FDA-Acceptance-for-Filing-of-New-Drug-Application-Resubmission-for-PEDMARK.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-23"
     },
     "end": {
      "date": "2022-09-23"
     },
     "iCalUID": "qedtvhim9ibul32g3tsfr9830k@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3304548027164000\"",
     "id": "95n4ln3s1c9iqogpg6s51u8q5g",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=OTVuNGxuM3MxYzlpcW9ncGc2czUxdThxNWcgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-05-11T13:00:13.000Z",
     "updated": "2022-05-11T13:00:13.582Z",
     "summary": "FOLD AMICUS THERAPEUTICS, INC. PDUFA",
     "description": "2022-08-29 The revised PDUFA action dates for miglustat and cipaglucosidase alfa are August 29, 2022 and October 29, 2022, respectively. https://www.sec.gov/Archives/edgar/data/0001178879/000110465922058218/tm2215096d1_ex99-1.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-08-29"
     },
     "end": {
      "date": "2022-08-29"
     },
     "iCalUID": "95n4ln3s1c9iqogpg6s51u8q5g@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3319408855292000\"",
     "id": "gnkp0h9guods5dddp2sum7jjns",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=Z25rcDBoOWd1b2RzNWRkZHAyc3VtN2pqbnMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-08-05T13:00:27.000Z",
     "updated": "2022-08-05T13:00:27.646Z",
     "summary": "VRTX VERTEX PHARMACEUTICALS INCORPORATED PDUFA",
     "description": "2022-09-04 The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of September 4, 2022. http://www.businesswire.com/news/home/20220804005875/en/Vertex-Reports-Second-Quarter-2022-Financial-Results",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-09-04"
     },
     "end": {
      "date": "2022-09-04"
     },
     "iCalUID": "gnkp0h9guods5dddp2sum7jjns@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
        "kind": "calendar#event",
        "etag": "\"3317508012304000\"",
        "id": "jhg825op1res052qf7hbqtt8kg",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=amhnODI1b3AxcmVzMDUycWY3aGJxdHQ4a2cgZXZnb2hvdm0ybTN0dXZxYWtkZjRoZmVxODRAZw&ctz=America/Los_Angeles",
        "created": "2022-07-25T13:00:06.000Z",
        "updated": "2022-07-25T13:00:06.152Z",
        "summary": "SPPI Spectrum Pharmaceuticals, Inc. FDA AdCom",
        "description": "2022-09-22 The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. During the first session of September 22, 2022, the committee will discuss new drug application (NDA) 215643, for poziotinib tablets, submitted by Spectrum Pharmaceuticals, Inc. The proposed indication (use) for this product is for the treatment of patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. Select patients with NSCLC for treatment with poziotinib based on the presence of HER2 exon 20 insertion mutations using an FDA-approved test. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-22-23-2022-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09222022",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.com",
         "displayName": "Adcom",
         "self": true
        },
        "start": {
         "date": "2022-09-22"
        },
        "end": {
         "date": "2022-09-22"
        },
        "iCalUID": "jhg825op1res052qf7hbqtt8kg@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3319927230384000\"",
        "id": "gsqruj07k9kq5blsg8f6l9221g",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=Z3NxcnVqMDdrOWtxNWJsc2c4ZjZsOTIyMWcgZXZnb2hvdm0ybTN0dXZxYWtkZjRoZmVxODRAZw&ctz=America/Los_Angeles",
        "created": "2022-08-08T13:00:15.000Z",
        "updated": "2022-08-08T13:00:15.192Z",
        "summary": "AMLX Amylyx Pharmaceuticals, Inc. FDA AdCom",
        "description": "2022-09-07 The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals Inc., for the treatment of amyotrophic lateral sclerosis. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-7-2022-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.com",
         "displayName": "Adcom",
         "self": true
        },
        "start": {
         "date": "2022-09-07"
        },
        "end": {
         "date": "2022-09-07"
        },
        "iCalUID": "gsqruj07k9kq5blsg8f6l9221g@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       }
   ]